ArticlePDF Available

Parkinsonism-hyperpyrexia syndrome after withdrawal of antiparkinsonian drugs and deep brain stimulation surgery

Authors:
  • Aviation General Hospital

Abstract and Figures

Background Parkinsonism-hyperpyrexia syndrome (PHS) is a rare but potentially fatal condition in patients with Parkinson’s disease. Deep brain stimulation (DBS) is a widely used and efficacious treatment for advanced Parkinson’s disease. Case presentationHere, we report a case of PHS in a patient who first underwent withdrawal of antiparkinsonian medications and then bilateral subthalamic nucleus DBS. Conclusions Patients should be advised to gradually decrease rather than suddenly stop antiparkinsonian medications when they must stop taking a medication and antiparkinsonian medications should be reintroduced as soon as possible after surgery.
No caption available
… 
Content may be subject to copyright.
C A S E R E P O R T Open Access
Parkinsonism-hyperpyrexia syndrome after
withdrawal of antiparkinsonian drugs and
deep brain stimulation surgery
Chun-Lei Han
1
, Yan Ge
2
, Da-Wei Meng
3
, Jian-Guo Zhang
3
and Fan-Gang Meng
1*
Abstract
Background: Parkinsonism-hyperpyrexia syndrome (PHS) is a rare but potentially fatal condition in patients with
Parkinsons disease. Deep brain stimulation (DBS) is a widely used and efficacious treatment for advanced
Parkinsons disease.
Case presentation: Here, we report a case of PHS in a patient who first underwent withdrawal of antiparkinsonian
medications and then bilateral subthalamic nucleus DBS.
Conclusions: Patients should be advised to gradually decrease rather than suddenly stop antiparkinsonian
medications when they must stop taking a medication and antiparkinsonian medications should be reintroduced as
soon as possible after surgery.
Keywords: Parkinsons disease, Deep brain stimulation, Parkinsonism-hyperpyrexia syndrome
Background
Parkinsonism-hyperpyrexia syndrome (PHS) is a rare but
potentially fatal condition in patients with Parkinsonsdis-
ease (PD) and is manifested by pyrexia, muscle rigidity, a
reduced level of consciousness, and autonomic instability.
It is generally believed that rapid withdrawal of antiparkin-
sonian drugs or abrupt changes in medication regimens is
the primary cause of this syndrome [1, 2]. Deep brain
stimulation (DBS) is a widely used and efficacious treat-
ment for advanced Parkinsons disease. Antiparkinsonian
drugs are transiently stopped before the procedure to
check the patients response during the procedure when
the patient is in the offstate. However, sudden discon-
tinuation of medications before or after DBS surgery had
been reported to provoke PHS [3, 4]. In addition, the sur-
gery itself may also provoke the condition. Here, we re-
ported a case of PHS in a patient who firstly underwent
withdrawal of antiparkinsonian medications and then bi-
lateral subthalamic nucleus (STN) DBS.
Case presentation
A 69-year-old woman with a 24-year history of Parkinsons
disease and the use of a variety of antiparkinsonian drugs
was admitted on February 27, 2014. Her disease had grad-
ually progressed, and the drugs were less effective, despite
increased dosages and changes in drug families. Before ad-
mission, she had been experiencing serious motor compli-
cations, including wearing-off and dyskinesia, and she was
taking levodopa/benserazide 500 mg/day, carbidopa/levo-
dopa 500 mg/day, selegiline 12.5 mg/day, trastal 150 mg/
day and amantadine 100 mg/day. After admission, the
drugs were gradually discontinued in order to alleviate the
dyskinesia (Fig. 1). However, it had no effect. A levodopa
test, which compared the Unified Parkinson Disease Rating
Scale Part III (motor score) before and after oral intake of
levodopa, showed a more than 30% improvement, which
indicated that the patient was a suitable candidate for
STN-DBS. Bilateral STN stimulation was commenced 5
days after admission. Eight hours before surgery, all PD
medications were stopped. Bilateral STN-DBS was per-
formed as described in the literature [4]. During the pro-
cedure, the patient was cooperative but exhausted. After
recovering from the general anesthesia, the patient was un-
able to communicate properly. During the night, the pa-
tient developed severe muscle rigidity, tremors, continuous
* Correspondence: fgmeng@ccmu.edu.cn
1
Beijing Neurosurgical Institute, Capital Medical University, No. 6 Tiantan Xili,
Dongcheng District, Beijing 100050, China
Full list of author information is available at the end of the article
˖ӧӝߥ͗ᇷፂܰመߥѫ͗
˖ӧӝߥ͗ᇷፂܰመߥѫ͗
CHINESE NEUROSURGICAL SOCIETY
CHINESE NEUROSURGICAL SOCIETY
CHINESE MEDICAL ASSOCIATION
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Han et al. Chinese Neurosurgical Journal (2017) 3:10
DOI 10.1186/s41016-016-0067-y
limb shaking, head tremor and trismus. She was febrile,
with a temperature of 39.8°C, and had diaphoresis, a pulse
rate of 132 beats/min, a respiratory rate of 24 breaths/min,
and sustained increasing in blood pressure up to 178/117
mmHg. Her consciousness gradually declined approxi-
mately 11 h after DBS. Laboratory tests were normal with
the exception of an elevated white blood cell count (18.0 ×
10
9
/L). A computed tomography (CT) scan of the brain
showed correct placement of the electrodes without evi-
dence of blood or other abnormalities. The next day, the
patient was admitted to the intensive care unit. Intravenous
fluid replacement and cooling of the body were initiated,
and complications were managed. In the next 7 days, a
series of tests were run to determine the cause of her con-
dition. An evaluation to determine potential sources of in-
fection was unrevealing. The evaluation of her febrile
condition included a chest x-ray, thyroid function tests,
routine stool tests, routine urine tests and a bacterial cul-
ture analysis; however, causative factors were not identified.
A cerebrospinal fluid (CSF) examination was also normal.
On the day of surgery and on postoperative days 1, 2, 3, 6,
and 12, brain CT showed normal postoperative changes;
however, a left frontal cerebral infarction occurred on the
2nd day after the operation (Fig. 2). On day 7 postopera-
tively, when infection, cerebral infarction and intracerebral
hemorrhage were all excluded, the diagnosis of PHS was
made. Antiparkinsonian medications were immediately re-
instated, and the patients symptoms began to improve.
Levodopa/benserazide was initiated at 250 mg/day and in-
creased to 500 mg/day, trastal was initiated at 25 mg/day
and increased to 150 mg/day, and amantadine 100 mg/
day per day was initiated (Fig. 1). By the 28th day after
surgery, the patients condition had gradually returned to
her preoperative status. Her consciousness recovered, and
her vital signs and laboratory tests returned to baseline
levels (Fig. 3).
Discussion
It has been reported repeatedly that acute withdrawal of
antiparkinsonian drugs in PD patients is considered to
be the sole cause of PHS. Apart from these medication-
related causes, physiological stressors, such as surgery, in-
jury, may also precipitate PHS [5]. Overnight withdrawal of
antiparkinsonian drugs in PD patients is widely performed
before DBS surgery to aid in the identification of the opti-
mal macrostimulation response site during surgery. Thus,
withdrawal of antiparkinsonian drugs combined with fur-
ther surgery is more likely to cause the complication than
either factor alone. Until now, about 5 cases of PHS after
DBS surgery have been documented; 3 of these cases oc-
curred due to perioperative drug cessation [4, 6, 7], while,
the other 2 cases occurred 6 and 8 days after antiparkinso-
nian drug dosages were reduced abruptly when the DBS
system was activated [3, 8]. In our case, the patient first ex-
perienced rapid reduction of antiparkinsonian drugs due to
dyskinesia. However, there was no improvement, which
eventually made her received DBS surgery. After surgery,
PHS happened and a left frontal cerebral infarction oc-
curred on the 2nd day after surgery. However, it is
uncertain whether the occurrence of cerebral infarc-
tion precipitated PHS or not. PHS occurred eventually
and was characterized by hyperthermia, extreme muscle
rigidity, autonomic instability, and altered consciousness.
At first, the patients condition was not considered to be
PHS because of a lack of experience with this disorder
and confounding factors such as the possibility of infec-
tion and cerebral infarction. The differential diagnosis in-
cluded infection, cerebral infarction and intracerebral
Fig. 1 The antiparkinsonian medication adjustment process of a 69-year-old woman diagnosed with Parkinsons disease and treated with DBS of
the STN. WBC, white blood cells. Row 1 indicates the date in day/monthformat
Han et al. Chinese Neurosurgical Journal (2017) 3:10 Page 2 of 4
hemorrhage. Infection was excluded based on CSF ana-
lysis, an x-ray, routine stool tests, routine urine tests and
bacterial culture analysis. CT of the brain revealed no intra-
cerebral hemorrhage but showed a left frontal cerebral in-
farction. Thus, in the first 7 days after surgery, only
symptomatic treatment was administered. Finally, when in-
fection, cerebral infarction and intracerebral hemorrhage
were all excluded, the diagnosis of PHS was made, and anti-
parkinsonian medications were gradually prescribed. The
patientcondition returned to her preoperative status with
clear consciousness and stable vital signs when discharged.
Conclusions
In summary, patients should be advised to gradually re-
duce rather than suddenly stop antiparkinsonian medica-
tions when they must stop taking a medication due to
significant side effects. Once a patient is seen to have very
high fever, extreme muscle rigidity, autonomic instability,
Fig. 3 The patients temperature (a) and white blood cell (WBC) counts during treatment (b). Her temperature and WBC counts increased after
the withdrawal of antiparkinsonian drugs and deep brain stimulation surgery but returned to normal after reinstatement of the medication
Fig. 2 Postoperative CT showed correct placement of the electrodes (a-b) and a suspicious left frontal cerebral infarction on the 2nd, 3rd, 6th
and 12th days after operation (c-f)
Han et al. Chinese Neurosurgical Journal (2017) 3:10 Page 3 of 4
and altered consciousness, PHS should be considered.
Moreover, antiparkinsonian medications should be rein-
troduced as soon as possible after surgery. In the event
that a patient develops PHS, it should be treated as a
neurological emergency. The key to success is early diagno-
sis and initiation of treatment. Finally, we should consider
the possibility that DBS surgery itself, as a physiological
stressor, may precipitate PHS.
Abbreviations
CT: Computed tomography; DBS: Deep brain stimulation; PD: Parkinsons
disease; PHS: Parkinsonism-hyperpyrexia syndrome; STN: Subthalamic nucleus
Acknowledgements
Not applicable.
Funding
This work was supported partly by Beijing Health System Advanced Health
Technology Talent Cultivation Plan (Grant No. 2011-3-032), China National
Clinical Research Center for Neurological Diseases (Grant No. NCRC-ND),
Beijing Municipal Administration of Hospitals Clinical medicine Development
of Special Funding Support (Grant No. ZYLX201305) and National Natural
Science Foundation of China (Grant No. 81527901).
Availability of data and materials
Not applicable.
Authorscontributions
CH contributed to the data collection and writing. YG and DM were involved
in the surgery and participated the data collection. JZ and FM were the
surgeons who performed the surgery. FM conceived of the study, and
participated in its design and coordination and helped to draft the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Written, informed consent was obtained from the patient for publication of
this case report and accompanying images.
Author details
1
Beijing Neurosurgical Institute, Capital Medical University, No. 6 Tiantan Xili,
Dongcheng District, Beijing 100050, China.
2
Department of Neurosurgery,
Beijing Fengtai Hospital, Beijing 100071, China.
3
Department of Neurosurgery,
Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China.
Received: 2 June 2016 Accepted: 8 December 2016
References
1. Newman EJ, Grosset DG, Kennedy PG. The parkinsonism-hyperpyrexia
syndrome. Neurocrit Care. 2009;10:13640.
2. Arora A, Fletcher P. Parkinsonism hyperpyrexia syndrome caused by abrupt
withdrawal of ropinirole. Br J Hosp Med. 2013;74:6989.
3. Urasaki E, Fukudome T, Hirose M, Nakane S, Matsuo H, Yamakawa Y.
Neuroleptic malignant syndrome (parkinsonism-hyperpyrexia syndrome)
after deep brain stimulation of the subthalamic nucleus. J Clin Neurosci.
2013;20:7401.
4. Kim JH, Kwon TH, Koh SB, Park JY. Parkinsonism-hyperpyrexia syndrome after
deep brain stimulation surgery: case report. Neurosurgery. 2010;66, E1029.
5. Hashimoto T, Tokuda T, Hanyu N, Tabata K, Yanagisawa N. Withdrawal of
levodopa and other risk factors for malignant syndrome in Parkinsons
disease. Parkinsonism Relat Disord. 2003;9 Suppl 1:S2530.
6. Linazasoro G, Van Blercom N, Castro A, Dapena MD. Subthalamic deep brain
stimulation masking possible malignant syndrome in Parkinson disease.
Neurology. 2004;63:58990.
7. Govindappa ST, Abbas MM, Hosurkar G, Varma RG, Muthane UB.
Parkinsonism Hyperpyrexia Syndrome following Deep Brain Stimulation.
Parkinsonism Relat Disord. 2015;21:12845.
8. Factor SA. Fatal Parkinsonism-hyperpyrexia syndrome in a Parkinsons
disease patient while actively treated with deep brain stimulation. Mov
Disord. 2007;22:1489.
We accept pre-submission inquiries
Our selector tool helps you to find the most relevant journal
We provide round the clock customer support
Convenient online submission
Thorough peer review
Inclusion in PubMed and all major indexing services
Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central
and we will help you at every step:
Han et al. Chinese Neurosurgical Journal (2017) 3:10 Page 4 of 4
... Regarding PHS in the perioperative period, Han et al. reported a 69-year-old female patient who developed worsening PD symptoms despite being on medical therapy [27]. The patient was a good candidate for STN-DBS and underwent surgery after her PD medications were withheld preoperatively. ...
... Regarding PHS in the perioperative period, Han et al. reported a 69-year-old female patient who developed worsening PD symptoms despite being on medical therapy [27]. The patient was a good candidate for STN-DBS and underwent surgery after her PD medications were withheld preoperatively. ...
Article
Full-text available
Parkinsonism-hyperpyrexia syndrome (PHS) is a rare, potentially fatal neurological emergency, that is seen in Parkinson's Disease (PD) patients and mimics neuroleptic malignant syndrome. The most common trigger for PHS is sudden withdrawal of anti-parkinsonian medications, specifically levodopa. However, it can also be due to Deep Brain Stimulation (DBS) device malfunction. In this work, we describe three cases of PHS; the first of which is related to DBS battery depletion, and the remaining two to dopaminergic withdrawal. Additionally, we will include the results of a literature review on PHS, its etiologies, presentation, and management.
... Se relaciona con el bloqueo de receptores dopaminérgicos o a la disminución de los precursores (5) dopaminérgicos a nivel central . Se caracteriza por un cuadro clínico distintivo de cambios en el estado (6) mental, rigidez, fiebre y disautonomía . La mortalidad es resultado de las manifestaciones de las (7) alteraciones autonómicas de la enfermedad y de las complicaciones sistémicas . ...
Article
Full-text available
Neuroleptic malignant-like syndrome or akinetic crisis is a rare and potentially lethal complication of the withdrawal of medication of patients with Parkinson's disease. We present the clinical case of 52-year man with 10-year history of Parkinson's disease who is being treated with levodopa-carbidopa. He consults for decreased level of consciousness and general muscular rigidity, related to the withdrawal of the medication 7 days before the onset of symptoms.
Article
Deep brain stimulator (DBS) has been widely performed for various medically refractory movement disorders. We report a 70's male patients with Parkinson's disease (PD) treated by DBS in addition to anti-parkinsonian drugs who underwent transurethral lithotomy under spinal anesthesia twice. We canceled his usual medications for PD, therefore, his blood pressure was higher than usual. His DBS was turned off in the operation room before induction of anesthesia. Both anesthesia techniques for TUL surgeries were completed by spinal anesthesia used by 0.5% hyperbaric bupivacine. Immediately after spinal anesthesia in both surgeries, severe rigidity, airway obstruction and conscious change emerged. These complications were suspected wearing-off-likes symptoms of PD, which were proved because of spinal anesthesia itself and/or DBS off effects. Autonomic hyperreflexia with severe hypertension, abnormal sweating and excessive oral secretion was gradually appeared after infusion of normal saline to obtain surgical fields of view, however, these symptoms disappeared after the end of infusion. It was suspected that the adverse events were due to low effects of spinal anesthesia on autonomic nervous system degenerated by Parkinson's disease. We turned on DBS immediately after the completion of surgeries, and resumed his oral medications on the next day of surgeries. There were no events in his courses. As there is little information and no standard anesthetic guidelines available on patients with DBS implant who are present for surgery, a careful management is needed to avoid complications. © 2019 Hiroshima University School of Medicine.All Rights Reserved.
Article
Background: People with Parkinson's disease (PD) treated with deep brain stimulation (DBS) with non-rechargeable implantable pulse generators (IPGs) require elective IPG replacement operations involving surgical and anesthesiologic risk. Life expectancy and the number of replacements per patient with DBS are increasing. Objective: To determine whether IPG longevity is influenced by stimulation parameters alone or whether there is an independent effect of the number of battery replacements and IPG model. Methods: PD patients treated with bilateral subthalamic DBS were included if there was at least one IPG replacement due to battery end of life. Fifty-five patients had one or two IPG replacements and seven had three or four replacements, (80 Kinetra® and 23 Activa-PC®). We calculated longevity corrected for total electrical energy delivered (TEED) and tested for the effect of IPG model and number of previous battery replacements on this measure. Results: TEED-corrected IPG longevity for the 1st implanted IPG was 51.3 months for Kinetra® and 35.6 months for Activa-PC®, which dropped by 5.9 months and 2.8 months, respectively with each subsequent IPG replacement (p < 10-6 for IPG model and p < 10-3 for IPG number). Conclusions: Activa-PC® has shorter battery longevity than the older Kinetra®, battery longevity reduces with repeated IPG replacements and these findings are independent of TEED. Battery longevity should be considered both in clinical decisions and in the design of new DBS systems. Clinicians need accessible, reliable and user-friendly tools to provide online estimated battery consumption and end of life. Furthermore, this study supports the consideration of using rechargeable IPGs in PD.
Article
Full-text available
The parkinsonism hyperpyrexia syndrome is a rare but potentially fatal complication seen in patients with Parkinson's disease. It is characterized by mental status changes, muscle rigidity, hyperthermia and autonomic dysfunction. Mortality of up to 4% has been reported but an additional one-third of patients have permanent sequelae.
Article
Full-text available
Neuroleptic malignant syndrome (NMS), also called parkinsonism-hyperpyrexia syndrome (PHS), is a severe, general, sometimes fatal, physical reaction, induced by sudden and strong blockade of dopamine receptors. When subthalamic nucleus (STN)-deep brain stimulation (DBS) is used on patients with Parkinson disease (PD), dopaminergic medications are transiently stopped prior to the procedure, and a reduction in the use of drugs is routinely attempted after the procedure. Although a sudden stop or abrupt reduction of dopaminergic medications may set the stage for NMS/PHS, only three cases have been reported after STN-DBS surgery. Here, we describe a 75-year-old woman with PD who experienced delayed onset, yet fatal, PHS after STN-DBS. Although STN-DBS might prevent or suppress PHS, its protective effect is not always complete. We must be aware that fatal PHS can occur when the use of medication for PD is reduced or altered, even when patients are under continuous STN stimulation.
Article
Deep brain stimulation is an alternative treatment for advanced Parkinson's disease. Levodopa medications are usually discontinued the night before surgery to localize the optimal response site to intraoperative macrostimulation. However, abrupt withdrawal of medication may result in side effects. We report a case of parkinsonism-hyperpyrexia syndrome (PHS), a rare complication resulting from discontinuation of antiparkinsonian medication, after a deep brain stimulation (DBS) procedure for bilateral subthalamic-nucleus (STN). A 66-year-old woman with an 11-year history of idiopathic Parkinson's disease was admitted for DBS. She had experienced wearing-off symptoms, severe peak-dose dyskinesia, and medication-induced side effects. Antiparkinsonian medication was discontinued 2 days before surgery because of severe drug-related complications. DBS for bilateral STN was performed uneventfully, but the patient was unconscious with fever, tachycardia, and hypertension after surgery. Levodopa and dopamine agonist replacement by nasogastric tube and hydration were immediately administered with conservative treatment for the hypertension, tachycardia, and fever. The patient's serum creatine kinase level increased to 786 U/L 3 days after the surgery and then decreased gradually as the patient's consciousness improved. Physicians should be aware of the possibility of PHS after a deep brain stimulation procedure. If the patient shows unexplained changes in consciousness with hyperpyrexia after surgery, PHS should be considered and adequate treatment should be given immediately to prevent death.
Article
The parkinsonism-hyperpyrexia syndrome (PHS) is a rare but potentially fatal complication seen in Parkinson's disease (PD) patients, most commonly following reduction or cessation of antiparkinson medications. Clinically it resembles neuroleptic malignant syndrome with rigidity, pyrexia, and reduced conscious level. There may be features of autonomic instability, and serum creatine kinase (CK) may be elevated. Complications of PHS include acute renal failure, aspiration pneumonia, deep venous thrombosis/pulmonary embolism, and disseminated intravascular coagulation (DIC). Management consists of dopaminergic drug replacement, supportive measures, and treatment of complications. The prognosis is improved with early recognition and management. Mortality of up to 4% has been reported, but an additional one-third of patients have permanent sequelae. Patients and physicians should be warned against sudden reduction in antiparkinson medications. PHS should always be considered in a patient with parkinsonism who presents with an acute deterioration in symptoms.
Article
A symptom complex identical to neuroleptic malignant syndrome (MS) is known to develop in patients with idiopathic Parkinson's disease (PD) or other forms of parkinsonism on long-term treatment with anti-parkinsonian drugs. In order to clarify the risk factors for parkinsonian MS, the authors retrospectively reviewed charts of consecutive inpatients with PD in the neurological departments at the three hospitals and found 16 episodes of parkinsonian MS in 14 patients. A survey of health status preceding MS disclosed that deterioration of parkinsonian symptoms alone may induce MS, while association of major risk factors, i.e. rapid discontinuation of anti-parkinsonian drugs, dehydration or infection may precipitate or exacerbate MS. Cerebral vascular disorders, mechanical brain injury or physiological stress could be other risk factors leading to MS.